---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-017275"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T02:44:40.244717+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharmaceuticals sells Rare Pediatric Disease PRV for $180M, extending cash runway to Q2 2028

## Summary
- Enters definitive agreement to sell PRV for $180M in cash; closing subject to HSR antitrust waiting period.
- PRV was awarded following FDA accelerated approval of KRESLADI (marnetegragene autotemcel) for LAD-I.
- Non-dilutive capital to support cardiovascular pipeline: Danon disease, PKP2-ACM, BAG3-DCM programs.
- Cash runway extended into second quarter of 2028, per CEO Gaurav Shah.
- PRV program reauthorized in February 2026, reinforcing incentive for rare pediatric disease therapies.

## SEC filing metadata
- accession: 0001140361-26-017275
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/0001140361-26-017275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/ef20071574_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-017275
- JSON: https://secwatch.observer/filing/0001140361-26-017275.json
- Plain text: https://secwatch.observer/filing/0001140361-26-017275.txt

## Source-grounded claims
- claim_id: 20b9666b9f3cf355f2564b0d4f8201d37e9bf88d
  claim: ROCKET PHARMACEUTICALS, INC. entered into PRV APA valued at $180 million (effective 2026-04-26).
  evidence_excerpt: On April 26, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/0001140361-26-017275-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.